Australia - englanti - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - normal immunoglobulin, quantity: 10 mg/ml - injection - excipient ingredients: glycine; water for injections - replacement therapy in: - primary immunodeficiency (pi) diseases; - symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment. immunomodulation in: - idiopathic thrombocytopaenic purpura (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count; - guillain barr? syndrome (gbs); - chronic inflammatory demyelinating polyneuropathy (cidp); - kawasaki disease.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 3.2 g - injection, solution - excipient ingredients: human immunoglobulin a; glycine; water for injections - evogam is indicated in adults and children for replacement therapy in: primary immunodeficiency disease (pid) and symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 0.8 g - injection, solution - excipient ingredients: glycine; human immunoglobulin a; water for injections - evogam is indicated in adults and children for replacement therapy in: primary immunodeficiency disease (pid) and symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

lumacina new zealand - water for injection 100% - solution for injection - 100 % - active: water for injection 100%

Malta - englanti - Medicines Authority

baxter healthcare limited - water for, injections - solvent for parenteral use - water for injections 100 percent weight/volume - all other non-therapeutic products

Malta - englanti - Medicines Authority

csl behring gmbh emil-von-behring-strasse 76, 35041 marburg, germany - water for, injection - solvent for parenteral use - water for injection - all other non-therapeutic products

Malta - englanti - Medicines Authority

baxter holding b.v. kobaltweg 49, 3542ce utrecht, netherlands - water for, injections - solvent for parenteral use - water for injections 100 % (w/v) - all other non-therapeutic products

Australia - englanti - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 60 mg/ml - injection, solution - excipient ingredients: maltose; human immunoglobulin a; water for injections - intragam p is indicated in replacement immunoglobulin g (igg) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. indications as at 21 july 2000: replacement igg therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; congenital acquired immune deficiency syndrome with recurrent infections. immunomodulatory therapy in: idiopathic thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogenic bone marrow transplantation; kawasaki disease. indications as at 25 february 2003: for replacement immunoglobulin g (igg) therapy in: primary immunodeficiency; myeloma and chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections, and; congenital acquired immune deficiency syndrome with recurrent infections. for immunomodulatory therapy in: idiopathic thrombocytopenic purpura (itp) in adults or children at high risk of bleeding or prior to surgery to correct platelet count; allogeneic bone marrow transplantation; kawasaki disease, and; guillain-barre syndrome (gbs).

Australia - englanti - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - equine antithymocyte immunoglobulin, quantity: 50 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections; glycine; hydrochloric acid - indications as at 11 april 2002 : atgam is indicated for renal transplant patients in whom reduction of peripheral t-lympocyte function as measured by rosette-forming cell assay could be desirable. during controlled clinical trials, this immunosuppression has been demonstrated in renal allograft recipients treated with atgam. when it was administered prophylactically with conventional immunosuppressive therapy, atgam delayed the onset of the first rejection episode, and when it was administered at the time of the first rejection, atgam resolved the acute rejection episode more frequently than did conventional therapy alone.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - water for injection 100% - solution for infusion - 100 % - active: water for injection 100% - sterilised water for injection is employed as a vehicle for medicinal products when water is a suitable solvent for dissolving or diluting injectable therapeutic substances for parental administration.